Trial Profile
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Entinostat (Primary)
- Indications CNS cancer; Ependymoma; Glioma; Lymphoma; Sarcoma; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 06 Oct 2021 Status changed from active, no longer recruiting to completed.
- 18 Aug 2021 Planned End Date changed from 30 Jun 2022 to 17 Aug 2022.
- 11 Mar 2021 Planned primary completion date changed from 30 Apr 2022 to 30 Jun 2022.